A continuous care treatment including nutritional ketosis in patients with T2D improved most biomarkers of CVD risk after 1 year. The increase in LDL-cholesterol appeared limited to the large LDL subfraction. LDL particle size increased, total LDL-P and ApoB were unchanged, and inflammation and blood pressure decreased (Cardiovascular Diabetology)
Diabetes News
Category: Cardiovascular
Bone markers and cardiovascular risk in type 2 diabetes patients
Higher osteopontin concentrations were associated with an increased CVD risk in type 2 diabetes patients. No consistent associations were found for the other five bone markers and risk of CVD in type 2 diabetes patients (Cardiovascular Diabetology)
Exercise capacity in diabetes mellitus is predicted by activity status and cardiac size rather than cardiac function
Exercise capacity is reduced in T2DM subjects relative to matched controls, whereas exercise capacity is preserved in T1DM. There was no evidence of sub-clinical cardiac dysfunction but, rather, there was an association between impaired exercise capacity, small LV volumes and sedentary behavior (Cardiovascular Diabetology)
Myocardial Infarction Subtypes in Patients with Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (From the LEADER Trial)
This analysis showed that liraglutide reduces the incidence of MIs in patients with type 2 DM at high CV risk, and may impact the clinical outcomes of MI (American Journal of Cardiology)
Impact of a multifactorial treatment programme on clinical outcomes and cardiovascular risk estimates
Our data support that short-term multifactorial treatment of patients with glycaemic dysregulation in a specialist outpatient setting is both achievable and effective, and associated with a clinically meaningful improvement in CVD risk (BMJ)
Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
The 3rd CVOT Summit of the D&CVD EASD Study Group discussed key results of recent CVOTs and new studies on lipid-lowering strategies in an interactive multi-disciplinary format. The summit discussed both potentials and limitations of current CVOT designs as well as strategies for the implementation of CVOT results in treatment guidelines. It also discussed potential elements for future design of CVOTs in diabetes and shaped the role for real-world data (Cardiovascular Diabetology)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
Our findings show cardiovascular safety across all GLP-1 receptor agonist cardiovascular outcome trials and suggest that drugs in this class can reduce three-point major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality risk, albeit to varying degrees for individual drugs, without significant safety concerns (The Lancet Diabetes & Endocrinology)
Trends in cardiovascular risk factor management in type 1 diabetes by sex
Although the adoption of intensive insulin therapy and obtaining ADA HbA1c recommendations are increasing, overall cardiovascular risk factor compliance remains low and merits further intervention (Journal of Diabetes and Its Complications)
Have We Really Demonstrated the Cardiovascular Safety of Antihyperglycemic Drugs? Rethinking the Concepts of Macrovascular and Microvascular Disease in Type 2 Diabetes
Physicians should not be falsely reassured by claims that a new treatment appears to have passed a narrowly-defined regulatory test. The management of diabetic patients often carries with it the risk of important cardiovascular consequences, even for drugs that do not overtly increase the risk of myocardial infarction or stroke (Diabetes, Obesity and Metabolism)
Cardiac Autonomic Neuropathy: Why Should Cardiologists Care about That?
Because diabetes mellitus often coexists with heart diseases and the most common methods used for diagnosis of Cardiac autonomic neuropathy (CAN) are based on ECG, not only diabetologists but also cardiologists should be responsible for diagnosis of CAN (Journal of Diabetes Research)
Translating recent results from the Cardiovascular Outcomes Trials into clinical practice
Recommendations from the Central and Eastern European Diabetes Expert Group (Cardiovascular Diabetology)
Glycated albumin and its variability as an indicator of cardiovascular autonomic neuropathy development in type 2 diabetic patients
Higher serum GA and its variability are significantly associated with the risk of developing CAN. Serum GA might be a useful indicator for diabetic complications and can enhance HbA1c’s modest clinical prediction for CAN (Cardiovascular Diabetology)
Cardiac autonomic neuropathy may play a role in pathogenesis of atherosclerosis in type 1 diabetes mellitus
CAN is significantly associated with higher CIMT in T1DM patients. CAN may play a role in pathogenesis of atherosclerosis in type 1 diabetes mellitus (Diabetes Research and Clinical Practice)
Insulin Therapy Increases Cardiovascular Risk: Time for a Sea of Change in Type 2 Diabetes Treatment
These associations support the findings of large-scale evaluations that strongly suggest that insulin therapy has a poorer short- and long-term safety profile than that found to many other anti-T2D therapies. The potential adverse effects of insulin therapy should be weighed against proven CV benefits noted for select other therapies for T2D as reported in recent large randomized controlled trials
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
In Chinese patients with coronary heart disease and impaired glucose tolerance, acarbose did not reduce the risk of major adverse cardiovascular events, but did reduce the incidence of diabetes (The Lancet Diabetes & Endocrinology)
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
In this long-term, pragmatic trial, incidence of cardiovascular events was similar with sulfonylureas (mostly glimepiride and gliclazide) and pioglitazone as add-on treatments to metformin. Both of these widely available and affordable treatments are suitable options with respect to efficacy and adverse events, although pioglitazone was associated with fewer hypoglycaemia events (The Lancet Diabetes & Endocrinology)
Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis
In this real-life analysis, the rate of hospitalizations for heart failure was significantly lower for patients initiating an SGLT2 compared with a DPP4 medication, specifically among older patients and those with diabetes complication (Cardiovascular Diabetology)
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
In patients with T2D and established CVD, a sizeable proportion without HF at baseline are at high or very high risk for HF outcomes, indicating the need for active case finding in this patient population. Empagliflozin consistently improved HF outcomes both in patients at low or high HF risk (European Heart Journal)
Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial
Only NT-proBNP strongly and consistently improved the prediction of heart failure in patients with type 2 diabetes beyond a wide range of clinical risk factors and biomarkers (Diabetes Care)
Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
There remains uncertainty about whether metformin reduces risk of cardiovascular disease among patients with type 2 diabetes, for whom it is the recommended first-line drug. Although this is mainly due to absence of evidence, it is unlikely that a definitive placebo-controlled cardiovascular endpoint trial among people with diabetes will be forthcoming (Diabetologia)
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 11
- Next Page »
Glycosmedia is also available as an App: